More abnormal cells linked to poorer ASCT outcomes in MDSMay 3, 2019Leukemia, Myelodysplasia, Transplantation
FDA approves ivosidenib frontline for certain AML patientsMay 3, 2019Leukemia, Myelodysplasia, TransplantationRare Diseases
Biomarker testing may transform treatment of acute GVHDApril 26, 2019Leukemia, Myelodysplasia, TransplantationPatient & Survivor Care
Idelalisib shows long-term safety, efficacy for relapsed CLLApril 26, 2019Leukemia, Myelodysplasia, TransplantationRare Diseases
Tagraxofusp produces high response rate in BPDCNApril 24, 2019Leukemia, Myelodysplasia, TransplantationRare Diseases
Complementary medicine use common among patients on TKIsApril 24, 2019Leukemia, Myelodysplasia, Transplantation
Model inspired by Netflix, Amazon may help guide MDS treatmentApril 23, 2019Leukemia, Myelodysplasia, Transplantation
Sorafenib plus GCLAM held safe in AML, MDS phase-1 studyApril 22, 2019Leukemia, Myelodysplasia, Transplantation
Study highlights lack of data on transgender leukemia patientsApril 19, 2019Leukemia, Myelodysplasia, TransplantationPatient & Survivor Care
Creating CAR T-cell therapies for T-cell malignanciesApril 16, 2019Lymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, TransplantationImmunotherapyImmuno-oncologyRare Diseases
Bendamustine/rituximab combo proves viable for comorbid CLLApril 10, 2019Leukemia, Myelodysplasia, TransplantationRare Diseases
Whole-genome sequencing demonstrates clinical relevanceApril 4, 2019Leukemia, Myelodysplasia, Transplantation
Ibrutinib sustained responses in refractory CLL in long-term follow-upMarch 27, 2019Leukemia, Myelodysplasia, Transplantation
